Skip to NavigationSkip to content

GSK to axe 650 positions across US workforce

Published on 06/09/18 at 10:12am

GlaxoSmithKline has announced its intention to cut 650 employees from its current US workforce, with the cutbacks coming as part of a global restructuring effort announced in July earlier this year.

The cutbacks are divided across a number of areas: 100 positions will be terminated in North Carolina, while 450 will be culled from the company’s sales force across all 50 states. One hundred more positions will also be eliminated at GSK’s Philadelphia office.

“The downsizing is intended to contribute to a major cost savings and improve the operational performance within certain sections of our Commercial and Commercial support operations,” GSK said in a letter to the NC Department of Commerce.

GSK employs around 15,000 in total in the US. All affected employees have been notified, and are expected to have vacated their roles by November this year.

The firm had a said that the restructuring effort would “significantly improve the competitiveness and efficiency of [its] cost base with savings delivered primarily through supply chain optimisation and reductions in administrative costs”. This commitment was reiterated in the company’s release: “The savings from this restructuring will be fully reinvested in R&D and to support commercialisation of new products, which will fuel innovation and our future growth,” the company said.

Matt Fellows

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches